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ABSTRACT 
A clinical affiliate hospital in Mississippi lacked a best practice clinical policy 
regarding the most appropriate skin preparation solution to use prior to neuraxial 
anesthesia. The evidence showed that alcoholic chlorhexidine is the optimal solution due 
to advanced characteristics which help reduce infection. Reducing infections can 
potentially reduce further complications for the patient, hospitalization length, and cost. 
Also, chlorhexidine was found safe to use for neuraxial anesthesia if cross-contamination 
is avoided and adequate drying time is allowed. Lastly, alcoholic povidone-iodine is an 
appropriate alternate if 0.5% chlorhexidine is unavailable.  
A best practice clinical policy was formulated and presented to a panel of experts, 
which included a certified registered nurse anesthetist, anesthesiologist, health policy 
expert, and infection preventionist due to their advanced knowledge and daily 
involvement with the current topic. Data was gathered via an evaluation tool which 
assessed the panels’ input on whether the findings were useful, were of high quality, and 
would have an impact on the facility.  
The majority of the panel strongly agreed that the information presented was 
useful, was of high quality, would pose an impact on the facility, and that the policy 
should be adopted. The general concern among the panel of experts was that 0.5% 
chlorhexidine is not readily available in individual applicators. Chlorhexidine with a 2% 
concentration is readily available, but this concentration is not recommended for lumbar 
puncture due to a higher risk of neurotoxicity. Therefore, 0.5% chlorhexidine in 70% 
alcohol should be chosen for skin preparation prior to neuraxial anesthesia as a result of 
strong supporting evidence.  
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CHAPTER I - INTRODUCTION 
Nosocomial infections or health acquired infections (HAIs), are infections 
acquired through the hospital that are often preventable yet can pose a risk on patient 
safety (Centers for Disease Control and Prevention [CDC], 2016). The CDC (2016) 
reported that 721,800 estimated total infections occurred in acute care hospitals in 2011, 
75,000 of which resulted in death. Furthermore, 38% of HAIs in surgical patients resulted 
in surgical site infections (SSIs) (Safe Care Campaign, 2017). Evidence shows that when 
health professionals are aware of HAIs and act to prevent them, the rate of HAIs 
decreases by 70% (CDC, 2016). Because HAIs are largely preventable, health 
professionals’ awareness of practices which lead to HAIs and attempt to reduce the rate 
of infections is crucial. In addition, reducing HAIs has the potential to decrease hospital 
reimbursement penalties (Centers for Medicare & Medicaid Services [CMS], 2018). 
While some efforts have been made successful in reducing the rates of HAIs over the 
years, continuing to research ways to reduce these infections is pertinent.  
 The operating room is a setting where distinct measures are taken to ensure 
sterility and prevent infectious complications postoperatively. Standard precautions, such 
as proper handwashing, hygiene, and wearing appropriate surgical gloves, masks, and 
gowns, can pose as barriers to contamination (American Association of Nurse 
Anesthetists [AANA], 2015; Campbell et al., 2014; Davies, 2017; Hebl, 2006). Another 
measure to reduce postoperative infection is choosing the most appropriate antiseptic 
solution to disinfect the skin prior to neuraxial anesthesia. Neuraxial anesthesia is a type 
of regional anesthesia, specifically a central neuraxial block, placed into either the 
epidural space or subarachnoid space (Nagelhout & Plaus, 2014). Osterman and Martin 
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(2011) reported that 61% of more than 1.8 million women in labor received 
epidural/spinal anesthesia in 2008, concluding that the majority of women in labor do 
receive neuraxial anesthesia. Improper use of neuraxial anesthesia, though, can cause 
extremely serious infectious complications. These complications can include skin 
infections, meningitis, epidural abscess, encephalitis, sepsis, bacteremia, and many others 
(Nagelhout & Plaus, 2014).  
Problem Description 
The absence of a best practice recommendation regarding the most appropriate 
skin antiseptic solution to use prior to neuraxial anesthesia presented a gap in the 
literature. Available knowledge has shown that chlorhexidine is the superior antiseptic 
solution of choice for overall skin antisepsis; however, compliance with this 
recommendation in regard to neuraxial anesthesia has been inconsistent. In addition, a 
clinical affiliate hospital in Mississippi lacks a clinical policy on the topic of which skin 
antiseptic solution should be used for neuraxial anesthesia. This finding was important to 
this investigation due to the increased risk for HAIs which affect patient safety, quality 
care, and hospital reimbursement. Therefore, the purpose of this Doctor of Nursing 
Practice (DNP) project was to analyze best practice for neuraxial anesthesia skin 
antiseptic solutions and develop a best practice policy recommendation based on these 
findings.  
Available Knowledge 
Due to the prevalence and severity of HAIs and SSIs, the inconclusive data 
regarding the primary antiseptic solution for neuraxial anesthesia, and the lack of a 
clinical policy regarding neuraxial anesthesia at a clinical affiliate hospital in Mississippi, 
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a thorough examination of available knowledge was conducted on the topic to clarify the 
data, analyze best practice for neuraxial anesthesia skin preparation, and develop a best 
practice policy. A literature matrix, shown in Appendix A, was created to synthesize the 
relevant evidence. The main themes of the literature reviewed were (a) the importance of 
standard precautions, (b) a comparison of two common skin antiseptic solutions, 
chlorhexidine and povidone-iodine, (c) the effects of alcohol in conjunction with 
antiseptic solutions, (d) the safety of chlorhexidine during neuraxial anesthesia, and (e) 
alternative solutions to alcoholic chlorhexidine.  
The Importance of Clinical Policies 
Hospital administrators and faculty create, approve, and implement policies 
within every department in order to promote standardization of practice and ultimately 
best ensure patient safety (PolicyMedical, n.d.). Numerous guidelines outline policies, 
such as current literature and accreditation organizations. Therefore, policies are written 
extremely clearly, cautiously, and precisely so that all involved will understand their 
duties and responsibilities. Because policies are very thorough, numerous components are 
involved in creating a policy, including a policy number, area, title, subject, effective 
date, and rationale (Boise State University, 2018).  
Standard Precautions 
Within all aspects and levels of nursing, standard precautions are required to 
ensure sterility and help prevent HAIs. These precautions include but are not limited to, 
thoroughly and appropriately washing hands, removing all jewelry, using sterile surgical 
gloves, and wearing surgical masks. Proper clinical practice guidelines include using 
standard precautions to promote optimal aseptic techniques (AANA, 2015; Campbell et 
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al., 2014). Hebl (2006) conducted a systematic review and found that standard 
precautions should be used to prevent or reduce infections. In addition, Davies (2017) 
discussed that using standard precautions can help prevent rare yet dangerous neuraxial 
infections.  
Lack of standard precaution adherence can cause HAIs, which lead to (a) further 
complications for the patient, (b) increased length of hospitalization, and (c) increased 
cost for the hospital (Kirkland, Briggs, Trivette, Wilkinson, & Sexton, 1999). When 
comparing infected to uninfected patients, Kirkland et al. (1999) found that (a) more than 
twice as many infected patients died during their initial hospitalization, (b) infected 
patients had almost twice as long hospitalizations, (c) infected patients were more likely 
to be readmitted to the hospital, and (d) infected patients contributed to almost twice as 
much direct costs during their initial hospitalization, a difference of $3,644 per person. 
Ultimately, standard precautions are crucial to prevent nosocomial infections and other 
complications in hospitals and should be of utmost priority. 
Chlorhexidine versus Povidone-Iodine 
Currently, chlorhexidine and povidone-iodine are the two leading skin antiseptic 
solutions for neuraxial anesthesia. Chlorhexidine has been shown to be the most 
effective, superior skin antiseptic solution than other alternatives, such as povidone-
iodine, due to advanced characteristics, mechanism of action, and ability to reduce 
infection rates. Chlorhexidine has advanced characteristics such as fast onset, increased 
duration, decreased incidence of skin reaction, superior efficacy, and adherence to the 
skin (AANA, 2015; AANA, 2017; Checketts, 2012; Davies, 2017; Edmiston et al., 2013; 
Fernandes, Fonseca, Rosa, Simões, &, Duarte 2011; Hui, Varadharajan, Yousefzadeh, 
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Davies, & Siddiqui, 2017; Mangram, Horan, Pearson, Silver, & Jarvis, 1999; New York 
School of Regional Anesthesia [NYSORA], 2017; Reynolds, 2008).  
The mechanism of action for chlorhexidine is likely the reason why chlorhexidine 
has such advanced characteristics and is thus considered the most superior skin antiseptic 
solution. Kinirons et al. (2001) found that their participants who received alcoholic 
chlorhexidine antiseptic solution preoperatively were less likely to have colonization of 
microorganisms compared to those who received aqueous povidone-iodine (p = 0.02). 
Other researchers found that the participants who were treated with chlorhexidine in 
alcohol showed significantly less bacterial colonization (14.4%) and reduced post-
operative surgical wound infection (2%) compared to the participants who were treated 
with povidone-iodine (31.2% and 3.2%, respectively) (Paocharoen, Mingmalairak, & 
Apisarnthanarak, 2009). Lastly, the AANA guidelines (2015) stated that chlorhexidine 
dressings for epidural catheters have shown to be effective in reducing skin entry-point 
colonization. Chlorhexidine’s ability to reduce microorganism and bacterial colonization 
as well as reduce skin entry-point colonization allows for it to be an appropriate and 
successful solution for preventing infections.   
In addition, chlorhexidine has shown through clinical studies to lower infection 
rates compared to povidone-iodine, which is likely due to advanced characteristics and 
mechanism of action (Darouiche et al., 2010; Edmiston et al., 2013; Noorani, Rabey, 
Walsh, & Davies, 2010). Another group of researchers conducted a meta-analysis that 
showed significant improvements in choosing chlorhexidine instead of povidone-iodine 
(Lee, Agarwal, Lee, Fishman, & Umscheid, 2010). First, chlorhexidine usage was 
associated with less SSIs compared to povidone-iodine (adjusted risk ratio, 0.64 [95% 
 6 
confidence interval, [0.51–0.80]). Second, chlorhexidine usage resulted in fewer positive 
skin cultures when compared to povidone-iodine (adjusted risk ratio, 0.44 [95% 
confidence interval, 0.35–0.56]). Third, after performing a cost analysis, the researchers 
found that choosing chlorhexidine would result in $16 to $26 savings per surgical case 
and $349,904 to $568,594 savings per year at the particular hospital evaluated (Lee et al., 
2010). Levin et al. (2011) found that their participants who received chlorhexidine and 
alcohol as their skin antisepsis prior to their gynecological laparotomies showed a 
significantly reduced rate of SSIs by 10% compared to their povidone-iodine counterparts 
(p = 0.011). Lastly, researchers who screened participants for Methicillin-resistant 
Staphylococcus aureus (MRSA) found that those who tested positive for MRSA and were 
treated with chlorhexidine showed positive results including reduced wound 
complications (Chen, Chivukula, Jacobs, Tetreault, & Lee, 2012). Therefore, 
chlorhexidine has been shown through numerous research studies to be effective in 
reducing SSI rates as a result of its mechanism of action and superior characteristics.  
The Effects of Alcohol Combined with Chlorhexidine 
While chlorhexidine alone has proven to be extremely effective and superior 
compared to other skin antiseptic solutions, alcohol advances the qualities of 
chlorhexidine, making the two in conjunction the most appropriate solution. Antiseptic 
solutions with alcohol are considerably more effective due to alcohol’s characteristics 
such as immediate onset, increased efficacy, broad spectrum range, decreased risk for 
complications, and cost-effectiveness (Fernandes et al., 2011; Hemani & Lepor, 2009). 
The Infection Control Guide for certified registered nurse anesthetists (CRNAs) and the 
Infection Prevention and Control Guidelines for Anesthesia Care both recommend 
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choosing chlorhexidine with alcohol for skin preparation as a result of characteristics 
from both solutions in conjunction (AANA, 2013; AANA, 2015). In fact, Hui et al. 
(2009) discovered that the majority of anesthesiologists surveyed choose chlorhexidine 
with alcohol as their primary antiseptic solution.  
The Safety of Chlorhexidine for Neuraxial Anesthesia 
Ample controversy has ensued involving chlorhexidine and its safety during 
neuraxial anesthesia; however, various researchers have found chlorhexidine to not only 
be safe but also appropriate for neuraxial anesthesia (Campbell et al, 2014; Edmiston et 
al., 2013; Hampl, Steinfeldt, & Wulf, 2014). Various sources report that chlorhexidine is 
safe to use as long as appropriate precautions are followed prior to skin puncture to 
prevent chlorhexidine from reaching the cerebrospinal fluid and causing neurologic 
complications. These preventative measures include (a) isolating the alcoholic 
chlorhexidine from other drugs and equipment, (b) allowing the chlorhexidine to dry 
adequately before puncturing the skin, and (c) checking or changing one’s gloves before 
continuing with the procedure (Campbell et al., 2014; CareFusion, 2014a). Avoiding 
cross-contamination can help prevent neuraxial complications (Davies, 2017). Alcoholic 
chlorhexidine is recommended to be applied twice for maximum efficacy and should be 
allowed adequate drying time, approximately 30 seconds after each application, prior to 
skin puncture (American Society of Anesthesiologists Task Force on Infectious 
Complications Associated with Neuraxial Techniques, 2011; Campbell et al., 2014; 
Davies, 2017).  
Additionally, the concentration of chlorhexidine is important to note since 
concentrations greater than 0.5% used for neuraxial anesthesia have been said to cause 
 8 
neurotoxicity (AANA, 2015). The concentration 0.5% chlorhexidine in alcohol is safely 
recommended for central nervous blocks (Campbell et al., 2014; CareFusion, 2014a). In 
addition, NYSORA (2017) recommends choosing 0.5% chlorhexidine in 70% alcohol for 
spinal anesthesia and lumbar puncture. While 0.5% chlorhexidine is the preferred 
concentration as it is the lowest and safest, evidence states that 2% concentration of 
chlorhexidine does not result in a higher rate of neurological complications (CareFusion, 
2014a; Sviggum et al., 2012). However, 2% chlorhexidine has not been approved by the 
Food and Drug Administration (FDA) for a lumbar puncture (CareFusion, 2014b).  
Alternative Solutions 
Although chlorhexidine in alcohol, specifically 0.5% chlorhexidine, has clinically 
shown to be the most superior antiseptic solution for neuraxial anesthesia, another 
appropriate option is available. As previously mentioned, alcohol added to chlorhexidine 
accelerates and improves the qualities of chlorhexidine. Therefore, alcohol added to 10% 
povidone-iodine can also be effective for neuraxial anesthesia, although not the preferred 
solution of choice (AANA, 2013; AANA, 2015; AANA, 2017; Macias et al., 2013). This 
alternative would be an appropriate secondary choice for neuraxial anesthesia if 0.5% 
chlorhexidine in alcohol was unavailable.  
Rationale 
A review of the evidence revealed a lack of a clinical best practice policy 
regarding which skin antiseptic solution should be chosen by CRNAs prior to neuraxial 
anesthesia. The validity of standard precautions, the importance of preventing HAIs and 
SSIs, and the potential to decrease hospital reimbursement rates reiterated the need for a 
relevant policy. Based on the available knowledge presented above, chlorhexidine, 
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specifically paired with alcohol, was recognized as the most superior skin antiseptic 
solution (Checketts, 2012; Darouiche et al., 2010; Kinirons et al., 2001; Lee et al., 2010; 
Levin et al., 2011; Noorani et al., 2010; Paocharoen et al., 2009). Choosing the most 
appropriate solution has the potential to show positive results for the patient and hospital, 
such as lower HAIs, improve patient care, decrease reimbursement penalties, and 
standardize practice among CRNAs as a result of a best practice clinical policy (CMS, 
2018; PolicyMedical, n.d.). Therefore, based on the available knowledge presented 
above, choosing 0.5% chlorhexidine in alcohol was recommended as the most efficient 
and appropriate for skin preparation prior to neuraxial anesthesia.  
Specific Aims 
The purpose of this DNP project was to analyze best practice for neuraxial 
anesthesia skin antiseptic solutions and develop a best practice policy recommendation 
based on these findings. The specific aim of investigating the two common neuraxial 
anesthesia skin antiseptic solutions, chlorhexidine, and povidone-iodine, was being 
conducted because neuraxial anesthesia is common, especially in pregnant women during 
labor, and that improper use of neuraxial anesthesia can result in serious complications, 
such as meningitis or sepsis. Therefore, the goal of this report was to reveal relevant 
evidence to develop a best practice policy recommendation for a clinical affiliate hospital 
in Mississippi. As a result, this new policy would assist with improving patient safety and 
quality of care, decreasing reimbursement penalties and standardizing practice among 
CRNAs by following protocol. 
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Summary 
Health acquired infections are largely preventable when health professionals are 
more aware and knowledgeable of the situation and best practice (CDC, 2016). Proper 
skin antisepsis prior to neuraxial anesthesia can aid in reducing HAIs. However, a gap in 
the literature was noted due to lack of a best practice clinical policy regarding the most 
appropriate skin preparation solution prior to neuraxial anesthesia. Current evidence 
shows various themes related to choosing the most appropriate skin antiseptic solution 
prior to neuraxial anesthesia to help reduce HAIs. The themes presented by evidence 
include (a) the importance of standard precautions, (b) the superiority of chlorhexidine to 
povidone iodine, (c) the beneficial properties of alcohol in conjunction with 
chlorhexidine, (d) the safeness of chlorhexidine during neuraxial anesthesia, and (e) the 
acceptable substitution of alcoholic povidone iodine if alcoholic chlorhexidine is 
unavailable (Checketts, 2012; Darouiche et al., 2010; Kinirons et al., 2001; Lee et al., 
2010; Levin et al., 2011; Noorani et al., 2010; Paocharoen et al., 2009).  
 Clinical policies are vital components of organizations to help promote 
standardization of practice and ensure patient safety (PolicyMedical, n.d.). Specifically, 
proposing a new clinical policy regarding proper skin antisepsis prior to neuraxial 
anesthesia would support reducing HAIs and hospital reimbursement penalties (CMS, 
2018). Therefore, the purpose of this DNP project was to develop a best practice policy 
recommendation based on current available knowledge regarding neuraxial anesthesia 
skin preparation.  
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CHAPTER II – METHODS 
Context 
The current best practice investigation regarding neuraxial anesthesia skin 
antiseptic solutions was conducted at a clinical affiliate hospital in Mississippi. The 512-
bed facility typically has a total census between 300 and 400 patients. On average, an 
estimated 10,400 total surgical cases are scheduled, including obstetric cases, per year. 
Many of these cases require neuraxial anesthesia. In addition, approximately 45 CRNAs 
are employed in this facility, all of whom administer neuraxial anesthesia if needed and 
make the choice of their preference for skin antisepsis.  
Intervention, Study of the Intervention, and Measures 
After completing clinical rotations at various surgical facilities in Mississippi, no 
distinct policy existed at a clinical affiliate hospital for which skin antiseptic solution, as 
well as appropriate application methods to use, prior to neuraxial anesthesia. In addition, 
a gap in the literature was noted regarding which solution is appropriate and 
recommended for skin preparation prior to neuraxial anesthesia specifically. Therefore, 
available knowledge was examined and synthesized to determine the best practice for 
skin preparation prior to neuraxial anesthesia. Search terms used to identify relevant 
information included “chlorhexidine,” “povidone-iodine,” “skin preparation,” “neuraxial 
anesthesia,” “epidural,” “guidelines,” and “application.” Literature databases used were 
Google Scholar, Academic Search Premier, CINAHL, Health Source: Nursing/Academic 
Edition, and MEDLINE. Applying these search terms in these databases using Boolean 
operators resulted in 1,037 articles. Inclusion criteria for narrowing the use of these 
articles were (a) publication during or following the year 1999, (b) comparisons between 
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chlorhexidine and povidone-iodine, (c) solutions used for neuraxial anesthesia, (d) 
appropriate concentrations for solutions, (e) guidelines for the appropriate solution, and 
(f) proper application methods for the solutions. Exclusion criteria for the articles were 
those which negated the inclusion criteria.  
Commonalities, as well as differences, were found among the reviewed evidence, 
but the most common theme studies showed was that chlorhexidine is the superior skin 
antiseptic solution for skin preparation prior to neuraxial anesthesia if chosen in the 
correct concentration and if applied properly (Checketts, 2012; Darouiche et al., 2010; 
Kinirons et al., 2001; Lee et al., 2010; Levin et al., 2011; Noorani et al., 2010; 
Paocharoen et al., 2009). Studies showed that failure to abide by recommendations 
regarding concentration and application can cause serious complications such as 
meningitis and sepsis (Davies, 2017).  
With the synthesized available knowledge, a report of findings, as shown in 
Appendix B, was created and presented to a panel of experts along with a best practice 
policy recommendation, shown in Appendix C. Meetings were requested for involvement 
among a panel of experts from a CRNA, an anesthesiologist, a health policy expert, and 
an infection preventionist. The CRNA and anesthesiologist were asked to participate on 
the panel due to their advanced knowledge and daily involvement in performing 
neuraxial anesthesia and choosing appropriate skin antiseptic solutions. The health policy 
expert was asked to participate due to her advanced knowledge of policy development 
and logistical information. Lastly, the infection preventionist was requested to join the 
panel due to her knowledge of the current hospital policies and cost associations. Each of 
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these members are experts in their field and would be able to provide adequate details 
and feedback on the current topic.  
An evaluation tool, shown in Appendix D, was developed and used to gather 
feedback on the presented data, including the usefulness of information, quality of work, 
and the potential impact on the facility. This feedback was used to alter the policy 
recommendation and develop an executive summary (Appendix E). Next, the executive 
summary and policy recommendation were presented to the chief anesthesiologist for the 
anesthesia department to share the best evidence policy recommendation regarding 
neuraxial anesthesia skin preparation with the facility.  
Consent to participate in research was gathered by each member of the panel of 
experts following an oral presentation of research procedures. An evaluation tool was 
administered to the panel of experts in-person along with the policy recommendation for 
feedback. The evaluation tool included questions which gathered expert opinion and 
feedback on the usefulness and quality of information, potential impact, and suggestions 
for additions to aide in revising the policy recommendation (Friedman, 2003; Ray, 2017). 
The participants were requested not to include any identifying information on their 
surveys; therefore, results were kept confidential. Data was kept on a personal computer 
which required passcode entry, and files were kept in a locked drawer. Data was retained 
until project completion, then all files were permanently deleted from the storage device 
and written documentation was shredded.  
Since no clinical policy existed at a clinical affiliate hospital in Mississippi 
regarding which skin antiseptic solution is best to use prior to neuraxial anesthesia and 
since a gap in the literature was noted, two best practice policy recommendation options, 
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shown in Appendix C, were presented to the chief anesthesiologist. The protocol for 
application of the chosen solution, based on the evidence, was two applications of the 
solution for 30 seconds each in back and forth strokes of the solution with at least 30 
seconds of dwell time following both applications (CareFusion, 2014a; Horlocker, 2010). 
Option A is that CRNAs will use 0.5% chlorhexidine with 70% alcohol for neuraxial 
anesthesia following the aforementioned protocol. Option B is that 10% povidone-iodine 
in alcohol will be used for neuraxial anesthesia due to strong supporting evidence stating 
that povidone-iodine is an appropriate alternative solution if chlorhexidine is unavailable.  
Steps 
1. The project was proposed to this DNP project’s team.  
2. After approval from the DNP project team, application for approval was 
submitted to the IRB through The University of Southern Mississippi (USM). 
The IRB approval letter is shown in Appendix F.  
3. Next, an anesthesiologist, CRNA, health policy expert, and an infection 
preventionist were requested to serve as a panel of experts. Each member of 
the panel was orally presented research procedures and provided consent to 
participate in research.  
4. Then, a report of findings (Appendix B) and a clinical policy recommendation 
(Appendix C) were developed based on available knowledge and presented to 
the panel of experts. The panel of experts was given the opportunity to 
provide feedback via an evaluation tool (Appendix D), which was used to 
alter the policy recommendation.   
 15 
5. An executive summary (Appendix E) was developed and presented to the 
chief anesthesiologist along with a copy of the updated policy 
recommendation.  
6. Lastly, the DNP project was evaluated by the DNP project team based on the 
provided rubric.  
7. Dissemination of information was at the USM graduate scholarship day in 
September of 2018.  
Analysis 
Qualitative data was collected via the evaluation tool (Appendix D), and feedback 
was gathered in face-to-face policy presentations. This data was entered into a table, 
shown in Table 1, to analyze common responses or concerns. This information was 
utilized to revise the policy recommendation to present along with the executive 
summary (Appendix E). No statistical analysis was done; however, the information was 
analyzed qualitatively.  
Ethical Considerations 
An ethical consideration to the policy was the possibility of providing two levels 
of care, should the anesthesia provider choose to use povidone-iodine (Option B) instead 
of 0.5% chlorhexidine in alcohol (Option A) for neuraxial anesthesia. Although Option A 
is the best solution to use based on available knowledge, Option B is in place for 
instances of allergy or unavailability of Option A. In addition, 2% chlorhexidine has not 
been approved by the FDA for lumbar puncture; therefore, choosing this concentration 
for neuraxial anesthesia would be an ethical consideration.  
 16 
Summary 
 A clinical affiliate hospital lacked a best practice clinical policy regarding which 
skin antiseptic solution should be chosen for skin preparation prior to neuraxial 
anesthesia. Therefore, available knowledge was examined and synthesized to determine 
the best practice for skin preparation prior to neuraxial anesthesia. The available 
knowledge showed that 0.5% chlorhexidine in alcohol is the superior skin antiseptic 
solution and that failure to abide by such recommendations can result in serious neuraxial 
complications.  
A report of findings (Appendix B) and a best practice policy recommendation 
(Appendix C) were created based on available knowledge and presented to a panel of 
experts. The panel of experts included a CRNA, an anesthesiologist, a health policy 
expert, and an infection preventionist, as they were deemed relevant stakeholders due to 
their advanced knowledge and daily involvement with the current topic. The panel of 
experts were individually provided with a copy of the report of findings and policy 
recommendation along with an evaluation tool (Appendix D) to gather feedback on the 
presented data, including the usefulness of information, quality of work, and the potential 
impact on the facility. This feedback was used to alter the policy recommendation and 
develop an executive summary (Appendix E), which was presented to the chief 
anesthesiologist to share with the anesthesia department.  
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CHAPTER III - RESULTS 
A panel of experts was given a report of findings (Appendix B) and a best 
practice policy recommendation (Appendix C) based on the available knowledge 
involving the optimal skin antiseptic solution to choose prior to neuraxial anesthesia. 
Data was gathered via an evaluation tool (Appendix D), which assessed members of a 
panel of experts’ input on whether the information presented through the report of 
findings was found useful, was of high quality, and would have an impact on the facility. 
The members of the panel were also given the opportunity to identify whether or not they 
believed the policy should be adopted at a clinical affiliate hospital in Mississippi along 
with the ability to provide feedback in-person or on the evaluation tool. The responses to 
the prompts and questions on the evaluation tool are shown in Table 1.  
The members of the panel of experts included a CRNA, an anesthesiologist, a 
health policy expert, and an infection preventionist, as they were deemed relevant 
stakeholders due to their advanced knowledge and daily involvement with the current 
topic. All four members of the panel strongly agreed that the information presented was 
useful and of high quality. Three of the members strongly agreed that the suggestions 
provided would have a potential impact on the facility while the other member agreed 
with this statement. All four members reported that they believe the best practice policy 
should be adopted. The main conclusion of feedback among the panel of experts was the 
concern that the recommended concentration is not readily available commercially. For 
instance, one member stated, “Availability of 0.5% chlorhexidine would be a barrier 
since we currently don’t have this concentration available.” Another member stated, “If 
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the manufacturer provided 0.5% chlorhexidine.” The panel of experts agreed with the 
policy recommendation as presented and offered no feedback for revision.  
Table 1  
Panel of Experts’ Beliefs on the Proposed Best Practice Policy 
Evaluation Tool 
Questions and 
Prompts 
Panelist #1 Panelist #2 Panelist #3 Panelist #4 
The information 
presented was 
useful.  
Strongly Agree Strongly 
Agree 
Strongly Agree Strongly 
Agree 
The information 
presented was of 
high quality.  
Strongly Agree Strongly 
Agree 
Strongly Agree Strongly 
Agree 
The suggestions 
provided will 
have a potential 
impact on the 
facility.  
Strongly Agree  Agree  Strongly Agree  Strongly 
Agree  
Do you believe 
this new best 
practice policy 
proposed should 
be adopted?  
Yes Yes Yes Yes 
Other Feedback “Strong 
recommendation. 
Something the IPs 
have been 
following for the 
past year. Very 
interested to see 
how this 
recommendation 
turns out!”  
“Availability 
of 0.5% 
chlorhexidine 
would be a 
barrier since 
we currently 
don’t have 
this 
concentration 
available.”  
“If the 
manufacturer 
provided 0.5% 
chlorhexidine.” 
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Summary  
 Qualitative data found via the evaluation tool showed that 100% of the panel of 
experts strongly agreed that the information presented was useful and of high quality, 
while 75% strongly agreed that the suggestions provided would have a potential impact 
on the facility. Each member of the panel of experts believed the best practice policy 
should be adopted. The general conclusion of feedback was the concern that the 
recommended concentration is not commercially available. The panel of experts provided 
no further feedback for revision of the policy. 
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CHAPTER IV – DISCUSSION 
Summary 
It is crucial for healthcare professionals to be updated with current research and 
use appropriate, evidence-based practice in order to improve patients’ outcomes, reduce 
HAIs, and reduce hospital expenses (Kirkland et al., 1999; Lee et al., 2010). Increasing 
health professionals’ awareness of HAIs can significantly decrease the rate of HAIs 
(CDC, 2016). In addition to aseptic techniques and standard precautions, another way to 
help reduce HAIs caused by SSIs is choosing the appropriate skin antiseptic solution for 
neuraxial anesthesia. Proper skin antisepsis prior to neuraxial anesthesia is vital due to the 
large number of neuraxial anesthesia administered daily, including the majority of 
laboring women who receive epidurals (Osterman & Martin, 2011). Additionally, 
improper neuraxial anesthesia administration can cause serious infectious complications 
(Nagelhout & Plaus, 2014).  
The absence of evidence-based recommendations and a policy at a clinical 
affiliate hospital in Mississippi regarding the most appropriate skin antiseptic solution 
prior to neuraxial anesthesia poses a risk on both the patient and hospital due to a lack of 
consistency and accountability of patient care regarding proper skin antisepsis. 
Chlorhexidine, particularly with alcohol, has clinically shown to be superior due to its 
advanced qualities including fast onset, long duration, and strong penetration compared 
to other antiseptic solutions; however, improper use of chlorhexidine can cause 
neurotoxicity. Chlorhexidine has been shown through numerous research studies to be 
effective in reducing SSI rates and hospital costs as a result of its mechanism of action 
and superior characteristics.  
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Synthesis of the currently available knowledge was that 0.5% chlorhexidine 
concentration with 70% alcohol is the most effective, appropriate skin antiseptic solution 
to use prior to neuraxial anesthesia if allowed to dry thoroughly after application and if 
cross-contamination is avoided. If 0.5% chlorhexidine is unavailable, evidence shows 
that 10% povidone-iodine in alcohol is an acceptable alternative solution. Increasing 
anesthesia providers’ awareness of the current research can increase their compliance 
with the new recommendation (Ioscovich et al., 2014). Therefore, a new policy based on 
this current evidence-based practice was proposed to the chief anesthesiologist to review 
current evidence and share the policy recommendation with the facility.  
Interpretation 
A synthesis of available knowledge involving skin antiseptic solutions to use prior 
to neuraxial anesthesia was individually presented in-person to each member of the 
chosen panel of experts, which included a CRNA, an anesthesiologist, a health policy 
expert, and an infection preventionist. This investigation conformed to multiple of the 
DNP Essentials, shown in Appendix G, which outline the fundamentals involved in 
obtaining a DNP degree (American Association of Colleges of Nursing, 2006). Following 
this presentation, the panel of experts was given the opportunity to provide feedback via a 
provided evaluation tool (Appendix D), which was used to edit the executive summary. 
This feedback was personally presented to the chief anesthesiologist via an executive 
summary (Appendix E), which included the policy recommendation.  
Limitations 
Limitations of the current investigation included a small sample size of the 
number on the reviewing panel and busy workstyle of the panel of experts. The report of 
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findings (Appendix B), policy recommendation (Appendix C), and the short, clear 
evaluation tool (Appendix D) were personally presented to each member of the panel of 
experts in an organized, succinct manner to minimize the limitation of the members’ 
business. Members of the panel of experts were also given the opportunity to 
confidentially mail in their response.  
Conclusion 
The final evidence-based policy recommendation has the potential to (a) establish 
standardization of practice, (b) best ensure patient safety, and (c) help reduce HAIs 
caused by improper skin antisepsis prior to neuraxial anesthesia. Based on the feedback 
from the panel of experts, if the manufacturer produced a convenient, individual 
applicator of 0.5% chlorhexidine, as recommended by the evidence, the facility would be 
more prone to using it; however, the manufacturer does not currently produce 0.5% 
chlorhexidine in individual applicators as it is not believed to be economically substantial 
(CareFusion, 2014). Therefore, future research should be conducted on the subject to aid 
in increasing awareness of the importance of proper skin antisepsis prior to neuraxial 
anesthesia to help decrease HAIs as well as to prompt the manufacturer to produce the 
lowest, safest concentration of chlorhexidine in convenient, individual applicators.  
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APPENDIX B - Report of Findings 
Report of Findings 
Background 
 Health acquired infections (HAIs) are largely preventable when health 
professionals are more aware and knowledgeable of the situation and best practice. Such 
infections affect numerous patients annually, can result in surgical site infections, and can 
be severe enough to result in death (Centers for Disease Control and Prevention [CDC], 
2016; Safe Care Campaign, 2017). Therefore, increasing health professionals’ awareness 
and knowledge of appropriate ways to prevent or reduce the risk of HAIs can make an 
effort in reducing these significant infections.  
 Standard precautions, such as proper handwashing and wearing appropriate 
surgical gloves and masks, can pose as barriers to contamination and help reduce the risk 
of HAIs (American Association of Nurse Anesthetists [AANA], 2015; Campbell et al., 
2014; Davies, 2017). Additionally, choosing the most appropriate antiseptic solution to 
use to disinfect the skin prior to neuraxial anesthesia can help reduce HAIs. Evidence 
shows that chlorhexidine is the superior antiseptic solution for overall skin antisepsis; 
however, compliance with this recommendation in regards to neuraxial anesthesia has 
been inconsistent. Therefore, the purpose of this Doctor of Nursing Practice (DNP) 
project is to analyze best practice for neuraxial anesthesia skin antiseptic solutions and 
develop a best practice policy based on these findings.  
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Available Knowledge 
 Current evidence shows various themes related to choosing the most appropriate 
skin antiseptic solution prior to neuraxial anesthesia to help reduce HAIs. The first theme 
is that standard precautions, including disinfecting the skin prior to neuraxial anesthesia, 
can help to prevent or reduce infections as well as reducing further complications for the 
patient, decreasing hospitalization, and decreasing hospital cost (Davies, 2017; Kirkland, 
Briggs, Trivette, Wilkinson, & Sexton, 1999). The second theme is that chlorhexidine has 
shown to be the most superior skin antiseptic solution as a result of its advanced 
characteristics, such as fast onset and increased duration, and its ability to reduce 
infection rates, microorganism and bacterial colonization, and skin entry-point 
colonization (AANA, 2015; Darouiche et al., 2010; Davies, 2017; Edmiston et al., 2013; 
Fernandes, Fonseca, Rosa, Simões, & Duarte, 2011; & Noorani, Rabey, Walsh, & 
Davies, 2010). The third theme found in the evidence is that alcohol advances the 
qualities of chlorhexidine, making the two in conjunction the most appropriate solution 
(AANA, 2015; Fernandes et al., 2011). The fourth theme is that chlorhexidine is safe to 
use for neuraxial anesthesia if appropriate precautions are followed prior to skin puncture 
(Campbell et al, 2014; Edmiston et al., 2013; Hampl, Steinfeldt, & Wulf, 2014). 
Preventative measures include (a) isolating the alcoholic chlorhexidine from other drugs 
and equipment, (b) allowing the chlorhexidine to dry adequately before puncturing the 
skin, and (c) checking or changing one’s gloves before continuing with the procedure 
(Campbell et al., 2014; CareFusion, 2014). The fifth and final theme is that alcoholic 
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povidone-iodine is an appropriate alternative solution if 0.5% chlorhexidine in alcohol is 
unavailable (AANA, 2015; Macias et al., 2013). 
Suggestions for Best Practice  
 As a result of the available knowledge, including (a) the importance of standard 
precautions to reduce HAIs, (b) the superiority of chlorhexidine mixed with alcohol, and 
(c) the safety of chlorhexidine during neuraxial anesthesia, 0.5% chlorhexidine in 70% 
alcohol is recommended for skin preparation prior to neuraxial anesthesia. If unavailable, 
alcoholic povidone-iodine is an appropriate alternative.  
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APPENDIX E – Executive Summary 
 
Executive Summary of Best Practice Policy Recommendation for Neuraxial Anesthesia 
Skin Antiseptic Solutions 
Kyle Adams 
The University of Southern Mississippi 
 
The Student Registered Nurse Anesthetist convened a panel of experts to evaluate 
the collective evidence and develop an evidence-based clinical policy recommendation 
on the most appropriate neuraxial anesthesia skin antiseptic solution. Presented is the 
executive summary of the full report, “Best Practice Policy Recommendation for 
Neuraxial Anesthesia Skin Antiseptic Solutions,” which will be printed and presented at 
the University of Southern Mississippi College of Nursing in September 2018.  
This policy recommendation regarding the use of 0.5% chlorhexidine in alcohol 
for skin preparation prior to neuraxial anesthesia is provided to promote standardization 
of practice and ultimately best ensure patient safety. The purpose of this quality 
improvement project was to analyze best practice for neuraxial anesthesia skin antiseptic 
solutions and develop a best practice policy based on these findings. 
The current policy recommendation is evidence-based and should be integrated 
with the anesthesia provider’s professional judgment and the individual patient’s needs 
and preferences.  
  
42 
 
Available Knowledge 
 A gap in the literature was noted due to lack of a best practice clinical policy 
regarding the most appropriate skin preparation solution prior to neuraxial anesthesia. 
Current literature shows various themes related to choosing the most appropriate skin 
antiseptic solution prior to neuraxial anesthesia to help reduce hospital-acquired 
infections. The first theme is that standard precautions, including disinfecting the skin 
prior to neuraxial anesthesia, can help to prevent or reduce infections as well as reducing 
further complications for the patient, decreasing hospitalization, and decreasing hospital 
cost. The second theme is that chlorhexidine has shown to be the most superior skin 
antiseptic solution as a result of its advanced characteristics, such as fast onset and 
increased duration, and its ability to reduce infection rates, microorganism and bacterial 
colonization, and skin entry-point colonization. The third theme found in the literature is 
that alcohol advances the qualities of chlorhexidine, making the two in conjunction the 
most appropriate solution. The fourth theme is that chlorhexidine is safe to use for 
neuraxial anesthesia if appropriate precautions are followed prior to skin puncture. These 
preventative measures include (a) isolating the alcoholic chlorhexidine from other drugs 
and equipment, (b) allowing the chlorhexidine to dry adequately before puncturing the 
skin, and (c) checking or changing one’s gloves before continuing with the procedure. 
The fifth and final theme is that alcoholic povidone-iodine is an appropriate alternative 
solution if 0.5% chlorhexidine in alcohol is unavailable.   
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Process 
Data was gathered via an evaluation tool which assessed members of a panel of 
experts’ input on whether the information presented through a report of findings was 
found useful, was of high quality and would have an impact on the facility. The panel of 
experts included a certified registered nurse anesthetist, an anesthesiologist, a health 
policy expert, and an infection preventionist, as they were deemed relevant stakeholders 
due to their advanced knowledge and daily involvement with the current topic. Each 
member of the panel was given the opportunity to identify whether or not they believed 
the proposed policy should be adopted along with an area to provide feedback. After 
discussing the report of findings and proposed policy, the majority of the panel of experts 
strongly agreed that the information presented was useful, of high quality, and would 
pose an impact on the facility. The panel also agreed that the policy should be adopted. 
The main feedback presented by the panel of experts was the concern that 0.5% 
chlorhexidine is not readily available in convenient individual packs.  
Policy Recommendation 
It is recommended that 0.5% chlorhexidine in 70% alcohol is used prior to 
neuraxial anesthesia based upon current evidence; however, this concentration is not 
readily available as a swab stick. Chlorhexidine with a 2% concentration is readily 
available as a swab stick but is not recommended for lumbar puncture due to its higher 
risk of neurotoxicity. Therefore, 0.5% chlorhexidine in 70% alcohol should be chosen for 
skin preparation prior to neuraxial anesthesia as a result of strong supporting evidence. 
  
44 
 
Alternatively, if 0.5% chlorhexidine in alcohol is unavailable, alcoholic povidone-iodine 
is an acceptable choice.  
 
 
Policy Area: Anesthesia Department Subject: Neuraxial Anesthesia 
Title of Policy: Skin Preparation for 
Neuraxial Anesthesia 
Number:  
Effective Date:  Supersedes:  
Approved Date:  
Revision Date:  
Approved by:  
1. Rationale or background to policy: to help reduce rates of hospital-acquired 
infections and surgical site infections. Standard precautions, such as proper 
handwashing, hygiene, and wearing appropriate surgical gloves, masks, and 
gowns, can pose as barriers to contamination. Available knowledge shows that 
0.5% chlorhexidine in alcohol is the most superior and safest skin antiseptic 
solution to use prior to neuraxial anesthesia. The literature supports chlorhexidine 
with alcohol as a result of its advanced characteristics, such as fast onset and 
increased duration, as well as its ability to reduce infection rates, microorganism 
and bacterial colonization, and skin entry-point colonization 
2. Policy: All anesthesia providers will choose 0.5% chlorhexidine in 70% alcohol 
for skin preparation prior to performing neuraxial anesthesia while also following 
standard precautions. If this concentration is unavailable, then 10% povidone-
iodine in alcohol will be chosen.   
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3. Procedure:  
1. All anesthesia providers will follow standard precautions before 
performing neuraxial anesthesia. Standard precautions include: (a) 
removing all jewelry and artificial nails, (b) performing appropriate hand 
hygiene, and (c) wearing appropriate sterile surgical gloves and masks. 
Wearing cover gowns is optional.  
2. All anesthesia providers will choose 0.5% chlorhexidine in 70% alcohol 
for skin preparation prior to performing neuraxial anesthesia. The 
anesthesia provider will apply two applications of the solution for 30 
seconds each in back and forth strokes with at least 30 seconds of dwell 
time following both applications, unless otherwise noted on the 
manufacturer’s instructions.  
3. If 0.5% chlorhexidine in 70% alcohol solution is unavailable, the 
anesthesia provider will choose 10% povidone-iodine in alcohol. The 
application method of the alcoholic povidone-iodine will follow the 
manufacturer’s instructions along with adequate drying time.  
4. If a patient has an allergy or sensitivity to one of the aforementioned 
solutions, the anesthesia provider will choose the alternative solution. 
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